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THIOL-CONTAINING COMPOUNDS FOR
THE REMOVAL OF ELEMENTS FROM
TISSUES AND FORMULATIONS THEREFOR

metal-speci?c binding sites may produce metal precipitates
that are unstable over time and under certain pH conditions.

Such unstable precipitates may release bound metal back into

the environment, thereby proving unsatisfactory as treatment
or remediation agents. Further, these reagents may form
simple metal sul?des Which bacteria are capable of methylat

CROSS REFERENCE TO RELATED
APPLICATIONS

ing (in the case of Hg, forming the Water-soluble cation,
MeHg”). Accordingly, there is a need for ligands Which not
only bind metals and main group elements, but also hind these

This application is a continuation-in-part of US. patent
application Ser. No. 12/892,464, ?led on Sep. 28, 2010,
Which in turn is a continuation of international patent appli
cation no. PCT/US10/50512, ?led on Sep. 28, 2010 and
claiming the bene?t of priority in US. Provisional Applica
tion Ser. Nos. 61/246,278, 61/246,282 and 61/246,360, all
three ?led on Sep. 28, 2009, the entire disclosures of each of
Which are incorporated herein in their entirety.

elements in such a manner as to form stable, insoluble pre

cipitates Which retain the contaminant element(s) over a Wide
range of environmental conditions and over extended periods
of time.
Likewise, it is knoWn to use a variety of chelators for

chelation therapy of metals. Many studies today re?ect the
increasing exposure of the population to mercury and other

toxic heavy metals. Examples of currently approved binders

FIELD OF THE INVENTION

for treating heavy metal toxicity such as mercury toxicity are

dimercaptopropanesulfonate (DMPS) and dimercaptosuc

The present invention relates to compounds utiliZed in
covalent binding to a Wide range of metals and main group

20

elements, and more speci?cally to sulfur-containing ligands
and the utiliZation of such to remove contaminants from

solids, liquids and gases.
BACKGROUND OF THE INVENTION

25

Heavy metal and main group element pollution is an exist

ing and groWing WorldWide problem. During the past feW
decades, federal and state governments have instituted envi
ronmental regulations to protect the quality of surface and
ground Water from contaminants. In response to these regu

30

DMPS and DMSA form bound sandWich complexes With
metal, Where for example tWo binder molecules bind to a
single mercury atom. This provides a Weaker attachment than

bonds betWeen the thiol (iSH) groups and the HG2+. Also,
based on their negatively charged properties, binders like

to precipitate contaminants from surface Water, ground Water
and soil. Examples of compositions and methods utiliZed in

DMSA, DMPS and EDTA have a non-speci?c attraction for
35

all metal ions, including the essential metals Ca“, Mg“,
Mn2+, etc. The rapid excretion of these binders from the body
through the urine can have the negative effect of depleting the
body of these essential metals. Deaths have occurred by

Pat. No. 6,586,600, the entire disclosure of Which is hereby

incorporated by reference.
There are numerous industrial and environmental situa

essential metal depletion by charged binding compounds dur

tions Where ligands capable of binding metals and main group
elements can be utiliZed for remediation purposes. For

referred to as “chelators,” are not truly chelators in the chemi
cal sense of the Word. This is because there is insuf?cient
space betWeen the sulfurs on adjacent carbon atoms to alloW
a large metal atom to bind to both sulfurs at the same time,
Which is a requirement for forming a true “chelate.” Rather,

Would be the case With a true chelator, Which Would form tWo

latory requirements, numerous products have been developed
precipitating metals from Water and soil are detailed in US.

cinic acid (DMSA), Which Were introduced during World War
II to combat industrial exposure to heavy metals. Conven
tional compounds such as DMPS and DMSA, While often

40

example, Waste Water issuing from Waste treatment facilities,
chlor-alkali industries, metal ?nishing industries and certain

ing a process called chelation therapy, and this medical treat
ment must therefore be done by an experienced physician.
Heavy metals such as mercury are typically lipid-soluble

municipal land?lls often present contamination problems.

or can pass through the cell membrane via native divalent

Similarly, the metal content of Water exiting both functional
and abandoned mines is a signi?cant environmental issue in
geographical areas With a heavy mining industry. Soil and

metal ion carriers (e. g. for Ca“, Mg2+) as the M2+ form, and
45

adipose, or fatty, tissue or in other tissues high in lipid content,
including Without limitation the central nervous system.

surface Waters located in areas near natural gas pump houses

suffer a similar metal contamination problem. Gasses emitted
from coal-?red poWer plants and the incineration of munici
pal and medical Waste contain mercury. Thus, there is a need

Indeed, mercury and other heavy metals preferentially parti
tion to and concentrate in the hydrophobic aspects of mam
50

for ligands capable of binding and removing metals and main
group elements from gasses, aqueous and non-aqueous solu
tions and solid substrates.
It is knoWn in the art to use sulfur-containing compounds to
bind heavy metals. For example, Thio-Red® is a chemical

Thus, the currently available, approved heavy metal bind
55

ers have several disadvantages With regard to their overall
chemical nature that could be improved on by the synthesis of
better-designed, true chelators that have safer excretory prop
erties such as higher a?inity for the metals and/ or main group
elements and excretion through the feces instead of the urine.

60

Such better-designed, true chelators Would desirably be
uncharged, lipid-soluble or hydrophobic compounds, or
alternatively convertible from Water soluble (for suitability
for delivery via the bloodstream) to lipid-soluble compounds
in the body, to alloW them to partition into the fatty (hydro

Water. This product is a complex aqueous solution of sodium

(With or Without potassium) thiocarbonate, sul?des, and other
sulfur species. Thio-Red® ultimately removes Cu, Hg, Pb,

metal sul?des (i.e. CuS, HgS, PbS, and ZnS), rather than
metal thiocarbonates. Sodium and potassium dialkyldithio

phobic) tissues Where the mercury or other heavy metal bur
den is primarily located. Further, such chelators Would pos

carbamates such as HMP-2000®, are also Widely used as

metal precipitants. HoWever, the limited ability of most
reagents presently used on a commercial basis to form stable,
covalent bonds With heavy metals is a major concern for
remediation applications. Reagents that lack su?icient or

mals, ?sh, and the like, such as fatty tissues, cell membranes,
lipid-containing areas of the interior of a cell, and the like.

reagent used for precipitating divalent heavy metals from

and Zn from aqueous solutions through the formation of

may therefore concentrate intracellularly and more so in the

65

sess loW or, better yet, no observable toxicity to mammals

alone in the absence of heavy metal expo sures. They Would be
true chelators that Would bind heavy metals and main group

US 8,575,218 B2
3

4

elements exceptionally tightly, preventing toxic effects and

In another aspect, the present invention relates to methods
of removing metals and/ or main group elements from a lipid
containing tissue in a human and/or animal body. The meth
ods comprise intravenously delivering an amount of a sulfur
containing chelate ligand as described above to a lipid
containing tissue in a body, forming a ligand-metal and/or

also preventing release or concentration in toxic form in any

organ of the body. Still further, desirably the chelators Would
be excreted through the biliary transport system of the liver
into the feces instead of through the kidneys (a very sensitive
organ to heavy metal exposure) and into the urine. Still yet
further, it Would be desirable to provide improved chelators
Which readily convert betWeen Water-soluble and lipid
soluble forms, alloWing excretion by the desired route, i.e.,
via the kidney for the Water-soluble form and via the biliary
transport system of the liver into the feces for the lipid-soluble

ligand-main group element complex(es), and excreting the
complex(es) from the body. We have observed that certain
prior art uncharged, hydrophobic compounds, such as those
disclosed in Us. Pat. No. 6,586,600 to AtWood et al., have

exceptionally loW toxicity When injected or ingested by test
animals. Disadvantageously, the Water-insolubility of these
hydrophobic compounds makes them poor candidates for
intravenous applications. Intravenous (IV) application has
the advantage of speed of general delivery and the ability to

form.
SUMMARY OF THE INVENTION

In one embodiment, chelate ligands are of the general
formula:
20

treat an unconscious patient. Therefore, in the present disclo
sure, analogs of uncharged, non-toxic chelators are described
Which may initially be provided as charged, Water soluble
compounds. These Water-soluble compounds are converted
in the blood to uncharged lipid soluble compounds Which can
enter the membranes and other hydrophobic aspects of cells
and tissues, and even cross the blood brain barrier.

25

Further, the present disclosure provides uncharged, non
toxic lipid soluble analogs that can be converted by intracel
lular enZymes once internaliZed into Water soluble chelators.

O

These same compounds can be treated externally With
enZymes (esterases) to make them Water soluble for IV appli

cations. This may be especially useful if treatment is required
that does not enter cells or cross the blood brain barrier and

still retain high heavy metal and/ or main group element a?in

ity.

Y

In one embodiment of this aspect, the described chelators

where R1 is selected from a group including benZene, pyri

35

dine, pyridin-4-one, naphthalene, anthracene, phenanthrene
and alkyl groups, R2 is independently selected from a group

including hydrogen, alkyls, aryls, a carboxyl group, carboxy
late esters, organic groups and biological groups, R3 is inde
pendently selected from a group including alkyls, aryls, a

40

nations of organic, organometallic and inorganic groups,
including Without limitation OH, COOH, NH2, HSO3, halo

carboxyl group, carboxylate esters, organic groups and bio
logical groups, X is independently selected from a group

gens, and the like. X may be one or more of hydrogen,

including hydrogen, lithium, sodium, potassium, rubidium,
cesium, francium, alkyls, aryls, a carboxyl group, carboxylate

45

phytochelatins, thiolsalicylate, organic groups and biological

carboxylate esters, a hydroxyl group, NH2, HSO3, halogens,
a carbonyl group, organic groups, biological groups, poly

halogens, organic groups providing thioethers and related
derivatives, or metals selected Without limitation from the
Group 1 and 2 elements recited in the Periodic Table of the
Elements, or may include charged molecules having a termi

esters, cysteine, homocysteine, glutathione, lipoic acid, dihy
drolipoic acid, thiophosphate, N-acetyl cysteine, mercap
toacetic acid, mercaptopropionic acid, y-glutamyl cysteine,
groups, n independently equals 1-10, m:1-6, Y is indepen
dently selected from a group including hydrogen, polymers,
silicas and silica supported substrates, and Z is selected from
a group including hydrogen, alkyls, aryls, a carboxyl group,

are thiol/thiolate compounds including an aromatic ring
structure, further including additional functional groups on
the organic ring structure and/ or on the pendent thiol chains.
A representative structure for the compounds is set forth
beloW. In that structure, Z andY may be a variety of combi

nal sulfhydryl include Without limitation glutathione, cys
50

55

teine, homocysteine, lipoic acid, dihydrolipoic acid, thio
phosphate, N-acetyl cysteine, mercaptoacetic acid,
mercaptopropionic acid, y-glutamyl cysteine, phytochelatins,
thiolsalicylate, and the like. The reference character n may
represent any integer from 1-10. Other aromatic groups con

mers, silicas and silica supported substrates, With the proviso

templated include naphthalene, anthracene, phenanthrene,

that when R1 represents an alkyl group, at least one X cannot

and the like as set forth above.

simultaneously represent hydrogen.
In another aspect, the present invention relates to methods
of removing metals and/or main group elements from a start

60

ing material. The methods comprise contacting a starting
material With an effective amount of a sulfur-containing che
late ligand as described above for a suf?cient time to form a

stable ligand-metal and/or ligand-main group element com
plex(es), said metal and/or main group element complex(es)
remaining essentially irreversibly bound to said ligand over a
range of acidic and basic pH values.

65
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FIG. 1 shoWs the Weight loss results of a thermogravime

-continued

teric analysis on Si60 from a temperature range of 30° C. to
1000° C. With a temperature increase of 20° C./min and a How

O

rate of 1 10/ 55 mmHg (inlet/outlet pressure) performed in air
01

I
Y

rate of 1 10/ 55 mmHg (inlet/outlet pressure) performed at air

Still further, particular aspects of the present disclosure are

atmosphere;

directed to pharmaceutically effective amounts and formula
tions of such chelators for removing metals and/or main

FIG. 3 shoWs the Weight loss results of a thermogravime
teric analysis on SiAB9 produced from a ?rst experimental
procedure from a temperature range of 30° C. to 1000° C.

group elements from human and/or animal body tissues, such
as for ameliorating oxidative stress, treating heavy metal or

With a temperature increase of 20° C./min and a How rate of

other toxicity, raising in vivo glutathione levels, as dietary
supplements, and the like. The pharmaceutically effective

110/55 mmHg (inlet/outlet pressure) performed at air atmo

sphere;

amount of the compounds in question may be administered in
any appropriate manner including Without limitation oral

administration, transdermal administration, nasal administra
tion, intravenous administration, suppository, and others.
As a dietary supplement, methods for such supplementa
tion include orally administering betWeen about 0.5 and about
40.0 mg of compound per kilogram of the mammal’s today

body Weight per day, although due to the lack of toxicity
higher dose levels are acceptable. Optionally, the compounds

20

110/ 55 mmHg (inlet/outlet pressure) performed at air atmo

sphere;
25

30

D, cysteine, cystine, glutathione, lipoic acid, and combina
tions.
In methods of removing heavy metals or other toxins from
mammalian tissues, the compound may be administered in
amounts of betWeen about 0.5 mg and about 60.0 mg per

35

40

As summarized above, the present invention relates to

transdermally, nasally, intravenously, by suppository, or other
appropriate routes. The compounds may be administered in
amounts of betWeen about 0.5 mg and about 100.0 mg per

priate, such as in cases of acute toxicity or high oxidative
stress. The compounds may be used to treat oxidative stress
resulting from virtually any source or cause, including With

45

and/or ligand-main group element complex(es), the novel
ligands are capable of forming covalent bonds With the metals
50

out limitation heavy metals, drugs such as acetaminophen,

and/or main group elements that may not be broken under
most acidic or basic conditions. The ligands of the present
invention are suitable for binding metals and/or main group
elements Which are in or are capable of being placed in a

positive oxidation state, including, but not limited to, yttrium,
55

lanthanum, hafnium, vanadium, chromium, uranium, manga
nese, iron, cobalt, nickel, palladium, platinum, copper, silver,
gold, Zinc, cadmium, mercury, lead, tin and the like. The
ligands of the present invention are also suitable for binding

capable of modi?cation in various, obvious aspects Without
departing from the invention. Accordingly, the draWings and
descriptions Will be regarded as illustrative in nature and not

novel sulfur-containing chelate ligands Which bind metals
and/or main group elements resulting in ligand-metal and/or
ligand-main group element complex(es) Which remain stable
at a Wide range of pH values. In forming the ligand-metal

xenobiotics, aging, infection, physical injury, and disease.
Other aspects of the present invention Will become appar
ent to those skilled in this art from the folloWing description
Wherein there is shoWn and described exemplary embodi
ments of this invention. As it Will be realiZed, the invention is
capable of further embodiments and its several details are

areas, and subsequently enZymatically returned to a hydro
philic state iii vivo.
DETAILED DESCRIPTION OF ILLUSTRATIVE
EMBODIMENTS

priate.

kilogram of total body Weight per day, although due to the
lack of toxicity of the compounds higher doses may be appro

FIG. 5 shoWs the chemical structures of various hydropho
bic chelators according to the present invention, Which are
converted to hydrophilic chelators Within the microenviron
ment; and
FIGS. 6a and 6b shoW the chemical structures of various
chelators according to the present invention, Which may be
introduced into a body in a hydrophilic state, reduced to a

hydrophobic state in the body for partitioning into lipid-rich

kilogram of total body Weight per day, although due to the
lack of toxicity of the compounds higher doses may be appro
Likewise, in methods for ameliorating oxidative stress,
suitable administration routes include administering orally,

FIG. 4 shoWs the Weight loss results of a thermogravime
teric analysis on SiAB9 produced from a second experimen
tal procedure from a temperature range of 30° C. to 1000° C.
With a temperature increase of 20° C./min and a How rate of

may be administered With one or more additional antioxi

dants or chelators. Exemplary supplemental antioxidants
include Without intending any limitation vitamin E, vitamin

atmosphere;
FIG. 2 shoWs the Weight loss results of a thermogravime
teric analysis on SiNH2 from a temperature range of 30° C. to
1000° C. With a temperature increase of 20° C./min and a How

m

60

as restrictive.

main group elements Which are in or are capable of being
placed in a positive oxidation state, hereinafter de?ned as

including gallium, indium, thallium, boron, silicon, germa
nium, arsenic, antimony, selenium, tellurium, polonium, bis
muth, molybdenum, thorium, plutonium and the like.

BRIEF DESCRIPTION OF THE FIGURES

In one aspect, the present invention relates to chelate

The folloWing detailed description of speci?c embodi

65

ligands consisting of an organic group from Which depends at

ments of the present disclosure can be best understood When

least one alkyl chain that terminates in a sulfur-containing

read in conjunction With the folloWing draWings, in which:

group. The chelate ligands may be of the general formula:
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multiple ligands. HoWever, metal and/or main group element
atoms may also be bound by the sulfur and/ or nitrogen atoms

of several ligands that include multiple alkyl chains. Accord
ingly, the ligands may form metal and/or main group element

complexes though the interactions betWeen the metal and/or
main group element atoms and the sulfur and/or nitrogen
atoms of a single ligand, as Well as form polymeric metal

and/or main group element complexes through the interac
tions betWeen the metal and/or main group element atoms and

the sulfur and/or nitrogen atoms of multiple ligands.
The compounds may be bonded to supporting material Y at
R3 . Depending on the value of m, Y may comprise polymers,

silicas, silica supported substrates or hydrogen. If m:1, then
Y may be selected from a group comprising hydrogen, poly
mers, silicas and silica supported substrates, alumina and
other metal oxide materials. If m>1, then each Y may be
independently selected from a group comprising hydrogen,

where R1 may be selected from a group comprising organic
groups that include, but are not limited to, benzene, pyridine,

polymers, silicas, silica supported substrates, alumina and

pyridin-4-one, naphthalene, anthracene, phenanthrene and
alkyl groups such as (CH2)y Where y:2-8, R2 may be inde
pendently selected from a group comprising hydrogen,
alkyls, aryls, a carboxyl group, carboxylate esters, other
organic groups that include, but are not limited to, acyls and
amides, and biological groups that include, but are not limited
to, amino acids and proteins such as cysteine, R3 may be

20

other metal oxide materials. Thus, Where m>1 , the compound
may bond to supporting material Y at a single R3 , at all of the
R3 groups, or any combination thereof. Furthermore, Y may
comprise ?ltration beads or be otherWise embedded or
impregnated in a ?ltration medium. For example, in one

25

embodiment, Y may comprise polystyrene beads such that the
sulfur-containing compounds are supported on the polysty

independently selected from a group comprising alkyls, aryls,
carboxyl groups, carboxylate esters, other organic groups that
include, but are not limited to, acyls and amides, and biologi
cal groups that include, but are not limited to, proteins and
amino acids such as cysteine, X may be independently

rene beads for the ?ltration of contaminants.

In one useful embodiment, the chelate ligands may be of

the general formula:
30

selected from a group comprising hydrogen, lithium, sodium,
potassium, rubidium, cesium, francium, alkyls, aryls, a car

boxyl group, carboxylate esters, cysteine, homocysteine, glu
tathione, lipoic acid, dihydrolipoic acid, thiophosphate,

35

N-acetyl cysteine, mercaptoacetic acid, mercaptopropionic
acid, y-glutamyl cysteine, phytochelatins, thiolsalicylate,
organic groups and biological groups, n may independently
equal 1-10, m may equal 1-6, Y may be independently
selected from a group comprising hydrogen, polymers, silicas
and silica supported substrates, and Z may be independently
selected from a group comprising hydrogen, alkyls, aryls, a
carboxyl group, carboxylate esters, a hydroxyl group, NH2,
HSO3, halogens, a carbonyl group, organic groups, biological
groups, polymers, silicas and silica supported substrates. In

40

groups, R2 may be independently selected from a group com

prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate
45

some embodiments n may independently equal to 1-6 or 1-4.
In some embodiments m may equal 1-2 or 4-6, and in certain

interesting embodiments, m equals 2. In embodiments Where
mz2, the sulfur atoms of multiple alkyl chains may share a
single X constituent. In such embodiments, X may be inde
pendently selected from a group comprising beryllium, mag

esters, organic groups and biological groups, R3 may be inde
pendently selected from a group comprising alkyls, aryls, a

carboxyl group, carboxylate esters, organic groups and bio
logical groups, X may be independently selected from a

group comprising hydrogen, lithium, sodium, potassium,
50

rubidium, cesium, francium, cysteine and glutathione, n inde
pendently equals 1-10, m:1-6, and Y may be independently
selected from a group comprising hydrogen, polymers, silicas
and silica supported substrates, With the proviso that when R1

nesium, calcium, strontium, barium and radium.
While not Wishing to be bound by any particular theory, it

represents an alkyl group, at least one X cannot simulta

is believed that the stability of the metal and/or main group

element complexes formed through utilization of the ligands

where R1 may be selected from a group comprising benZene,

pyridine, naphthalene, anthracene, phenanthrene and alkyl

55

of the present invention is derived from the multiple interac

neously represent hydrogen.
In another useful embodiment, chelate ligands may be of
the genera formula:

tions betWeen the metal and/or main group element atoms and

the sulfur and/or nitrogen atoms on the ligand. Accordingly, it
is believed that the sulfur and/or nitrogen atoms form a mul
tidentate bonding arrangement With a metal and/ or main
group element atom. In embodiments of ligands that include

60
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multiple alkyl chains (i.e., mz2), a metal and/or main group
element atom may be bound through interactions With the

multiple sulfur and/or nitrogen atoms of the ligand. In
embodiments of ligands that include a single alkyl chain (i.e.,
m:1), a metal and/or main group element atom may be bound
through interactions With the sulfur and/ or nitrogen atoms of

65
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where R1 may be selected from a group comprising benzene,
Z

pyridine, naphthalene, anthracene, phenanthrene and alkyl
groups, R2 may be independently selected from a group com

prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate
esters, organic groups and biological groups, R3 may be inde
pendently selected from a group comprising alkyls, aryls, a

carboxyl group, carboxylate esters, organic groups and bio

ACHZ).

logical groups, X may be independently selected from a

group comprising hydrogen, lithium, sodium, potassium,

|

rubidium, cesium, francium, cysteine and glutathione, n inde
pendently equals 1-10, m:1-6, andY may be independently
selected from a group comprising hydrogen, polymers, silicas
and silica supported substrates.
In another useful embodiment, the present invention
relates to chelate ligands consisting of an organic structure
from Which depend tWo alkyl chains terminating in sulfur
containing groups. The chelate ligands may be of the general
formula:

OYRYO
/N

N

(CH2)n

20

where R1 may be selected from a group comprising benZene,

pyridine, pyridin-4-one, naphthalene, anthracene, phenan
threne and alkyl groups, R2 may be independently selected
from a group comprising hydrogen, alkyls, aryls, a carboxyl
group, carboxylate esters, organic groups and biological
25

groups, R3 may be independently selected from a group com

prising alkyls, aryls, a carboxyl group, carboxylate esters,
organic groups and biological groups, X may be selected

from a group comprising beryllium, magnesium, calcium,
strontium, barium and radium, n independently equals 1-10,
30

CH

( 2% S—X

ACHZ).
X—S

and Z may be independently selected from a group compris

Z

ing hydrogen, alkyls, aryls, a carboxyl group, carboxylate

Il

esters, a hydroxyl group, NH2, HSO3, halogens, a carbonyl
group, organic groups, biological groups, polymers, silicas
and silica supported substrates.

OYRYO
/N\R2 R2/N

(CHm

Y may be independently selected from a group comprising

hydrogen, polymers, silicas and silica supported substrates,

In another useful embodiment, the present invention
relates to chelate ligands consisting of a ring structure from

WCH».
40

Which depend tWo alkyl chains terminating in sulfur-contain
ing groups. The chelate ligands may be of the general for
mula:

where R1 may be selected from a group comprising benZene,

pyridine, pyridin-4-one, naphthalene, anthracene, phenan
threne and alkyl groups, R2 may be independently selected
from a group comprising hydrogen, alkyls, aryls, a carboxyl
group, carboxylate esters, organic groups and biological

45

o

0

groups, R3 may be independently selected from a group com
Y— R3

prising alkyls, aryls, a carboxyl group, carboxylate esters,
organic groups and biological groups, X may be indepen
dently selected from a group comprising hydrogen, lithium,

strates.

In another useful embodiment, the present invention
relates to chelate ligands consisting of an organic structure
from Which depend tWo alkyl chains terminating in sulfur
containing groups. However, in this embodiment, the tWo

R3 —Y or

\ R2

R2 /

ml)"

sodium, potassium, rubidium, cesium, francium, cysteine and
glutathione, n independently equals 1-10, Y may be indepen
dently selected from a group comprising hydrogen, polymers,
silicas and silica supported substrates, and Z may be indepen
dently selected from a group comprising hydrogen, alkyls,
aryls, a carboxyl group, carboxylate esters, a hydroxyl group,
NH2, HSO3, halogens, a carbonyl group, organic groups,
biological groups, polymers, silicas and silica supported sub

N

50

ACHZ).
s—X

o

55

o

/

(CH2).
60

—

Y— R3

N

R2

s—X

R2

/

\CH».

X—8

R3

Y

Where R2 may be independently selected from a group com

prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate

sulfur atoms of the tWo alkyl chains share one X constituent.

esters, organic groups and biological groups, R3 may be inde
pendently selected from a group comprising alkyls, aryls, a

The chelate ligands may be of the general formula:

carboxyl group, carboxylate esters, organic groups and bio
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logical groups, X may be independently selected from a

6,586,600, chelate ligands of the above general formula,
Wherein the R3 groups (as Well as the R2 groups) comprise
hydrogen, both n equal 1, and bothY comprise hydrogen, may

group comprising hydrogen, lithium, sodium, potassium,
rubidium, cesium, francium, cysteine and glutathione, n inde
pendently equals 1-10, andY may be independently selected

be referred to as “B9.”

In another useful embodiment of B9, the chelate ligands
from a group comprising hydrogen, polymers, silicas and 5
are of the formula:
silica supported substrates. As disclosed in US. Pat. No.

0

o

N

N
o

<CH2>n\S

s/cHm
\

/

o
HO
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O

s

N
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o

N

/

H

0

NH2

\H

H\
o
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s

O

y
on

o

HZN
on

o

/N

N\(CH
)
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T
0
HO

ill

O
o

|

s
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N

o
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H
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o

OH
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on

o
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65 Where n independently equals 1-10. Chelate ligands of this
general formula may be referred to as “glutathione B9” or
abbreviated to “GB9.”
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In one useful embodiment of GB9, the chelate ligand is of
the formula:

NH

HN

j
/
o

H

S

S

o

\S

s

|

N

N

\H

Ho

H\
o

N

o

N

/

H

O

0
0H
0

HZN
oH

0&0
NH

/
o

H

HN

S

S

o

\S

s

|

N

N

\H

Ho

H\
O

N

N

/

H

o

0
0H
0

HZN
oH

In another useful embodiment, the present invention
relates to chelate ligands consisting of a ring structure from

50

Which depend tWo alkyl chains terminating in sulfur-contain
ing groups. In this embodiment the tWo sulfur atoms of the
tWo alkyl chains share one X group. The chelate ligands may

be of the general formula:

Where R2 may be independently selected from a group com

prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate
esters, organic groups and biological groups, R3 may be inde
pendently selected from a group comprising alkyls, aryls, a

carboxyl group, carboxylate esters, organic groups and bio
(CH2) ” \ s

65
X—s

or

logical groups, X may be selected from a group comprising

beryllium, magnesium, calcium, strontium, barium and
radium, n independently equals 1-10, andY may be indepen

US 8,575,218 B2
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dently selected from a group comprising hydrogen, polymers,
silicas and silica supported substrates.

In another useful embodiment of AB9, the chelate ligands
are of the formula:

In another useful embodiment, the chelate ligands are of
the formula:

where R1 may be selected from a group comprising benzene,

pyridine, naphthalene, anthracene, phenanthrene and alkyl
groups, R2 may be independently selected from a group com

prising alkyls, aryls, a carboxyl group, carboxylate esters,
organic groups and biological groups, X may be indepen
dently selected from a group comprising hydrogen, lithium,

sodium, potassium, rubidium, cesium, francium, cysteine,

30

prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate

and glutathione, n independently equals 1-10, andY may be
independently selected from a group comprising hydrogen,
polymers, silicas and silica supported substrates. Chelate
ligands of these general formulas may be referred to as “acid

esters, organic groups and biological groups, n independently
equals 1-10, and Y may be independently selected from a
group comprising hydrogen, polymers, silicas and silica sup
35

B9” or abbreviated to “AB9.”

R

I

ported substrates.
In another useful embodiment of AB9, the chelate ligands

In one useful embodiment of AB9, the chelate ligands are
of the formula:

o

Where R2 may be independently selected from a group com

are of the formula:

o
0

N

o

O

O

N

O

\R2 R2/

NH

45

HN

Y—O

O—Y or

1

S—H

OYRYO
/

(CH2).

N\

R2 R2

/

N\

H—S

(CH2).

O

O

NH

where R1 may be selected from a group comprising benZene,

HN

pyridine, naphthalene, anthracene, phenanthrene and alkyl
groups, R2 may be independently selected from a group com

O

prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate
esters, organic groups and biological groups, X may be inde
pendently selected from a group comprising beryllium, mag
nesium, calcium, strontium, barium and radium, n indepen
dently equals 1-10, and Y may be independently selected
from a group comprising hydrogen, polymers, silicas and
silica supported substrates.

O

S—H
Y—O

65

H—S
O—Y

Where Y may be independently selected from a group com

prising hydrogen, polymers, silicas and silica supported sub
strates.
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In another useful embodiment of AB9, the chelate ligands
are of the formula:

O

O

O

O
N

Y—o

N
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OH
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NHZ

H
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o

H
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0

OH

HZN
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Where R2 may be independently selected from a group com-

group comprising hydrogen, polymers, silicas and silica sup

prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate 65 ported substrates. Chelate ligands of this general formula may
esters, organic groups and biological groups, nindependently
equals 1-10, and Y may be independently selected from a

be referred to as “glutathione AB9” or abbreviated to
“GAB9.”
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In one useful embodiment of GAB9, the chelate ligand is of
the formula:

O

#QYO
NH

HN

O
O
S
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WhereY may be independently selected from a group com-

Where PS may be polystyrene or a co-polymer containing

prising hydrogen, polymers, silicas and silica supported sub- 50 polystyrene- In one even more Particular embodiment, PS
snares,
may be chloromethylated polystyrene-co-diVinylbenZene

(2% DVB, 200-400 mesh).
In one particular embodiment of the material supported
AB9, the material may be deriVatiZed prior to the addition of
AB9, or its equivalent, providing a structure With the formula:

In another useful embodiment of AB9, the AB9 may be
material supported With a structure of:

O

O

O #QY O
\

NH

60

HN

O

OH

SH

HS
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Alternatively, AB9 may be loaded onto amine functional

-continued
R1

iZed silica (Silica-NH2). In one exemplary embodiment,

0y YO

Silica-NH2, produced by binding y-aminopropyltriethoxysi
lane on silica-60 (Si60), may be re?uxed in a solution of AB9
in ethanol producing a structure of the formula:

<CHZ>K

K

N\

R2 R2

/

N\

(CH2).

O

O

Y
O

W

Y

0
SH

where R1 may be selected from a group comprising benZene,

HS

pyridine, naphthalene, anthracene, phenanthrene and alkyl
groups, R2 may be independently selected from a group com

In an alternative preparation, SiNH2 may be treated With
AB9 in the presence of dicyclohexylcarbodiimide (DCC) to
facilitate the coupling of the AB9 to the amine of the PS.

prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate
20

In another useful embodiment, the chelate ligands are of
the formula:

esters, organic groups and biological groups, X may be inde
pendently selected from a group comprising beryllium, mag
nesium, calcium, strontium, barium and radium, n indepen
dently equals 1-10, andY is a methyl group.
In another useful embodiment of MEAB9, the chelate
ligands are of the formula:

o

R

1

o

O Y
N

Y/\O
CH

( 2k

\R2 R2/

O
N

O/\Y or

0

o

o

ACHZ).

o
N

Y/\O

\R2

R2 /

N

O/\Y or

(CH2)n

(CH2)n

SH
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HS/

0

o

/

Y

N

<CH2>n

Y

R2

R2

/

N\

(CH2).

0

0
SH

HS

where R1 may be selected from a group comprising benZene,

pyridine, naphthalene, anthracene, phenanthrene and alkyl

45

groups, R2 may be independently selected from a group com

prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate
esters, organic groups and biological groups. X may be inde
pendently selected from a group comprising hydrogen,

lithium, sodium, potassium, rubidium, cesium, francium,

50

OH

Y

Where R2 may be independently selected from a group com

prising hydrogen, alkyls, aryls, a carboxyl group, carboxylate

cysteine and glutathione, n independently equals 1-10, andY
is a methyl group. Chelate ligands of these general formulas
may be referred to as “methyl ester AB9” or abbreviated to
“MEAB9.”

(0

Y
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In one useful embodiment of MEAB9, the chelate ligands

esters, organic groups and biological groups, n independently
equals 1-10, andY is a methyl group.
In another useful embodiment of MEAB9, the chelate
ligands are of the formula:

are of the formula:

60

0

O

O

YAQKK

O
NH

HN

SH

HS

fkOAY or

